AstraZeneca strikes $40 million AI drug discovery deal with Insitro
The multi-year partnership will target severe liver and heart conditions, with insitro eligible for up to $1.46 billion in development and commercial milestone payments
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
